CEPI expands partnership with WBVR to advance Rift Valley Fever vaccine· CEPI to invest up to $25.9 million, with support from the EU, in trials in East Africa to assess a vaccine candidate against Rift...
Novel Rift Valley fever vaccine dosed in Phase I human trial LARISSA consortium reaches milestone Novel Rift Valley fever vaccine dosed in Phase I human trial The first healthy volunteer was dosed...
Unprecedented rains and flooding in Sudan puts millions at risk of vector-borne diseasesHeavy rains and flooding have affected 875,000 people across Sudan. More than 4.5 million people at increased risk of arboviral diseases...